DIgging into the Phase 1 Data of CRISPR therapeutics' CTX310 gene therapy for cardiovascular disease.

Executed on:Jun 16, 2025 10:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Oregon Health & Science University

Associate Director of the Center for Preventive Cardiology and Professor at Oregon Health & Science University with a specific clinical focus on inherited lipid disorders.
Personally manages ~500 patients with HeFH within the center for Preventive Cardiology.
Research focuses on PCSK9 physiology and its impact on lipoprotein metabolism; engaged in clinical trials testing novel lipid modulating therapeutics.

Interview Goal

This call will feature a discussion regarding the top-line data from the phase 1 clinical trial of CTX310 Targeting ANGPTL3 in patients with cardiovascular disease.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.